Myriad Genetics (NASDAQ:MYGN) released its earnings results on Sunday. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.09, Briefing.com reports. The company had revenue of $173.10 million for the quarter, compared to analyst estimates of $155.36 million. Myriad Genetics had a negative net margin of 32.49% and a negative return on equity of 4.07%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.08) EPS.
Shares of NASDAQ MYGN traded up $1.22 during mid-day trading on Tuesday, hitting $31.62. The stock had a trading volume of 756,991 shares, compared to its average volume of 760,862. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.75 and a current ratio of 2.95. Myriad Genetics has a 1 year low of $10.54 and a 1 year high of $33.97. The business has a 50 day moving average price of $29.58 and a two-hundred day moving average price of $24.03. The firm has a market cap of $2.43 billion, a P/E ratio of -12.16 and a beta of 1.71.
Separately, SVB Leerink raised their price objective on Myriad Genetics from $20.00 to $33.00 and gave the company a “market perform” rating in a research note on Tuesday, March 2nd.
Myriad Genetics Company Profile
Myriad Genetics, Inc, a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool.
See Also: Book Value Per Share in Stock Trading
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.